|
業務類別
|
Biotechnology |
|
業務概覽
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
| 公司地址
| 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 617 945-5576 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cogentbio.com |
| 員工數量
| 258 |
| Mr. Cole Pinnow |
Chief Commercial Officer |
美元 482.27K |
23/04/2026 |
| Dr. John Edward Robinson, PhD |
Chief Scientific Officer |
美元 532.04K |
23/04/2026 |
| Dr. Jessica Sachs, M.D. |
Chief Medical Officer |
美元 549.39K |
23/04/2026 |
| Mr. John Green |
Chief Financial Officer and Principal Accounting Officer |
美元 510.68K |
23/04/2026 |
| Mr. Evan Kearns |
Chief Legal Officer and Corporate Secretary |
-- |
23/04/2026 |
| Mr. Andrews R. Robbins, M.B.A. |
Director, Chief Executive Officer and President |
美元 724.55K |
23/04/2026 |
|
|
| Dr. Christopher Cain, PhD |
Independent Director |
23/04/2026 |
| Mr. Peter Harwin |
Chairman of the Board |
23/04/2026 |
| Ms. Arlene M. Morris |
Independent Director |
23/04/2026 |
| Mr. Matthew E. Ros |
Independent Director |
23/04/2026 |
| Dr. Karen Jean Ferrante, M.D. |
Independent Director |
23/04/2026 |
| Mr. Andrews R. Robbins, M.B.A. |
Director, Chief Executive Officer and President |
23/04/2026 |
| Mr. Todd E. Shegog |
Independent Director |
23/04/2026 |
|
|
|
|
